Moreover, dysregulation of Tim-3 expression is not limited to T cells, as ample evidence shows that it affects functionality of innate immunity cells, including NK cells, DCs, mast cells and macrophages (MΦs) [13], thus making Tim-3 a suitable candidate for cancer immunotherapy [12]. Here, HAVCR2 is linked to cancer.